TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in CBCL score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in BMI from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in blood pressure percentile from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in sedentary behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in healthy diet
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Single Item Craving Test Session Difference Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Experiencing Adverse Events Defined as Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Combined Unique Active lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decrease From Baseline in Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Postpartum bipolar disorder relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of SIBO/SIFO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Level of protein C, S and AT, TAT, P1+2 and D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of subjects who completed the survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WOMAC scale change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Objective response rate (ORR) as assessed by RECIST 1.1 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of response (DOR) as assessed by RECIST 1.1 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pediatric Quality of Life Inventory Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resolution time of emphysema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC(0-last))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's adherence to medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in passive hamstring stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in severity of Organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average severity of Organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline SPECT image
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Patient progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Adverse Reactions (ARs)
Endpoint domain: Adverse events/effects
Primary endpoint: salivary oxidative stress values: TAS level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary oxidative stress values: TOS level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary LL-37 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic Vancomycin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glomerular Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety of the participant
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Verbal Rating Scale (VRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recovery of renal functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Integrated Palliative Outcomes Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline of echo intensity of quadriceps and biceps femoral muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline stiffness of patellar tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline young modulus of patellar tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in C-peptide area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in accrual rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of axial movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: velocity of axial movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceleration of axial movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global symptom score (GSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure and Timing Change of Velopharynx, Tongue Base, Low Pharynx and Upper Esophageal Sphincter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Length-for-age Z-score (LAZ) at 12 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average net costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lesion size of Bowen's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Haemostatic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Self-Care Inventory (SCI) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biting force measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with HGD or early ACA detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of lesions with HGD or early ACA detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Image quality analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Stepping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lane Width Optimization Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurence of Dose Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response Rate in Participants with R/R Lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Smears with Difficulty in Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IKDC-Subjective score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Days to Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Office Systolic Blood Pressure Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: breast tissue concentration of lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: breast tissue concentration of water
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: breast tissue concentration of collagen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast tissue concentration of total hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: breast tissue concentration of oxygenated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: urinary metabolites of endocrine disrupting chemicals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute change in serum phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in health-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants achieving 75% exercise completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Empowerment level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the ROC curve for severe diarrheal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Concentration-Time Curve Over the Dosing Interval (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in average pain intensity on Brief Pain Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in pain intensity on Western Ontario McMasters University Osteoarthritis Index (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of gemcitabine and epirubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenolics and derived metabolites in colon tissues, plasma and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gene expression profiling in colon tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3+ toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Unsolicited symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Breakthrough infection
Endpoint domain: Adverse events/effects
Primary endpoint: Mean cerebral blood flow velocity (CBFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Patients Requiring Rescue Medication for Breakthrough Nausea or Emesis
Endpoint domain: Adverse events/effects
Primary endpoint: Adequate Relief in Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six minutes walk distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Operative Cognitive Dysfunction (POCD)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: time to ureteral patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants with a Positive Serum Immunoglobulin G (IgG) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Breast milk concentration of carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Major adverse limb events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain distress rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: clinical efficacy of Sunitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants consuming healthier meals
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Number of Participants With >= Grade 2 Autoimmune Events or Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience at Least a 3-fold Higher PAP-specific T-cell Frequency or Proliferation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Timed Walk Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neck Disability Index (NDI) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: muscle or vessel shadow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to Maintain Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of vertebral fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Personal/social skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Educational skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Gastro-oesophageal insertion angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Contact span (of stomach on oesophagus)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median Progression Free Survival Time
Endpoint domain: Mortality/survival
Primary endpoint: Infant length at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant hemoglobin at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Investigator-rated improvement rate of glabellar lines at maximum frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject-rated improvement rate of glabellar lines at maximum frown
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subject-rated satisfaction at each cycle after treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants remaining in the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of days the Misfit Shine 2 is worn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant satisfaction with sleep education and Misfit Shine 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length for age Z-score (LAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Attenuated Mumps Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Correct esophageal catheter balloon position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of patients with undetectable serum HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instrumental Activities of Daily Living Scale (IADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Medical Outcomes Study HIV (MOS-HIV) Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pulmonary Thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response Rate (RECIST1.1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects with post cesarean endometritis
Endpoint domain: Adverse events/effects
Primary endpoint: Composite overall response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Receiver Operating Characteristic curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Procollagen Type I Intact N-Terminal Propeptide (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in C-terminal telopeptide (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Bone mineral density (BMD) - multiple sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Positivity rate of rtPCR-SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AMDC Product-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time at which maximum observed plasma concentration occurs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of the drug in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Deoxy/Oxy Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of acute radiation dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in breast cancer specific symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stomach Motor Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in adiponectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Local cortical hemodynamic change (oxy-Hb, deoxy-Hb, and total Hb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of the screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secondary Attack Rate (SAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Movement Imagery Questionnaire-Children (MIQ-C)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental Chronometry for Timed Up and Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Solicited Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Unsolicited Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: 7-day cessation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Activity Score 28 (DAS-28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate Specific Antigen (PSA) >= 50% Response Rate (PSA50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of lumbar spine BMD at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of 12 month treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Sleep (Total Sleep Time)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: mean duration of crying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline interleukin 6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline interleukin 1β (IL1β)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline interleukin 10 (IL10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline cytokine Tumor necrosis factor (TNFα)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline Mcp1 (Monocyte Chemoattractant Protein-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Life Participation for Parents
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Primary failure of access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rivaroxaban plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Study Drug-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in the Number of Binge Days Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression as Measured by CES-D
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregiving Burden as Measured by Burden Inventory
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Caregiver's Self Report of Physical Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient-reported Stiffness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sugar-sweetened beverage consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Water consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oropharyngeal leak airway pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak change from baseline of PCWP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak change from baseline of CI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative bioavailability of risedronate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Staphylococcus Aureus Abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response to Evaporative (Air) Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemorrhagic transformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: days with diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dopamine loss detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes